This is a US news story, published by markets.businessinsider.com, that relates primarily to Moderna news.
For more US news, you can click here:
more US newsFor more Moderna news, you can click here:
more Moderna newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from markets.businessinsider.com, you can click here:
more news from markets.businessinsider.comOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Vaccine makers. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest vaccines news, Vaccine news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
mRNA vaccinesmarkets.businessinsider.com
•Health
Health
85% Informative
Moderna , Novavax , and CureVac saw double-digit gains, while Pfizer and GSK also rose.
Moderna won a $176 million award from the US government in July to develop the shot.
The CDC reported the first death from bird flu in the US on Monday .
VR Score
88
Informative language
88
Neutral language
53
Article tone
formal
Language
English
Language complexity
48
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
6
Source diversity
2
Affiliate links
no affiliate links
